RECENT NEWS

The British In Vitro Diagnostic Association (BIVDA) has confirmed the appointment of Helen Dent as Chief Executive, following a successful period as Interim Chief Executive. Helen will lead BIVDA in championing the medical diagnostics industry to politicians, policymakers, media and relevant stakeholders and in supporting members to improve patient outcomes.

UK start-up Presymptom Health has raised £1.5m to help accelerate time to market of its AI-driven sepsis and infection tests - with the company aiming to roll-out its technology to the NHS from mid-2025.

A blood test which could help thousands of people receive earlier, more targeted, lung cancer treatments is being trialled by the NHS. The circulating tumour DNA (ctDNA) test, which will be offered to 10,000 patients by next March, can identify genetic variants in a tumour through a simple blood sample.

The National Pathology Imaging Co-Operative (NPIC) is re-running its 2023 educational webinar series on digital pathology, ‘Innovation into Practice’.

Innovate UK is pleased to announce the winners of a funding competition to develop new clinical tools for dementia and neurodegeneration. Ten new projects will receive funding for identification, development and commercialisation of biomarker tools and technologies.

Beckman Coulter Life Sciences has launched its new CytoFLEX nano Flow Cytometer – the first purpose-built nanoscale flow cytometer for research use only that enables detection to at least 40 nm, enabling 30-50% more data creation.

Owkin and University Hospitals Birmingham NHS Foundation Trust (UHB) have announced a new five-year research partnership to use artificial intelligence (AI) to accelerate the screening and diagnosis of a range of diseases, starting with colorectal cancer.

QDx Pathology Services, an independent anatomical, molecular and clinical pathology laboratory serving medical professionals and facilities throughout the United States, is working with Proscia, a leading provider of digital and computational pathology solutions, to innovate its practice. The laboratory has deployed Proscia’s software to enable its pathologists to work faster and more confidently.

A new collaboration between the UK Health Security Agency (UKHSA) and The Pirbright Institute has been launched to support the development of vaccines against Henipavirus – a genus of viruses including Nipah virus. The research has been funded by the Medical Research Council.

A new mpox vaccine is being tested in the UK, as the virus continues to spread in many parts of the world. The mPower trial is testing the effectiveness of an investigational mRNA vaccine for mpox. The study is delivered by NIHR Clinical Research Network (CRN) and sponsored by Moderna.

Coronary heart disease (CHD) is a major global health problem, especially among people with type 2 diabetes. Researchers at the German Center for Diabetes Research (DZD), Helmholtz Munich, and Ludwig-Maximilians-University Munich (LMU) have identified novel protein biomarkers that are associated with the development of CHD in people with and without diabetes.

An international consortium of researchers specialising in human challenge studies is embarking on a US$57 million project to develop advanced, virus-blocking coronavirus vaccines that could stop SARS-CoV-2 and other coronaviruses from infecting people.

A new study shows Lunit’s AI-powered cancer diagnostic solutions SCOPE HER2 and SCOPE ER/PR significantly improve pathologist concordance and accuracy, paving the way for improved breast cancer molecular subtype analysis for informed decision-making and precision patient care.

End-to-end digital pathology solution provider OptraSCAN has announced the introduction of a combined image management and image storage solution, to enable and simplify the digital transformation of pathology laboratories. The OptraSCAN IMAGEPath image management system is an open platform that can easily integrate with scanners from multiple manufacturers and over 20 different image formats, in addition to being compatible with external third-party AI applications for pathology.

The Science and Technology Facilities Council’s (STFC) Hartree Centre and the Mersey Care NHS Foundation Trust have announced a strategic partnership to advance artificial intelligence (AI) in healthcare across the trust to optimise patient outcomes.

Roche has this week introduced navify Analytics, a new suite of cloud-based solutions that provide actionable insights to optimise operational and financial outcomes in laboratories and point-of-care (POC) settings.

Beckman Coulter Diagnostics and Fujirebio have announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.

Oxford Nanopore Technologies and AI-driven genomic decision support software company SeqOne have announced a new partnership, which will enable end-to-end analytical workflows from sample to report, focusing on rare diseases in the short-term and oncology in the longer-term.

Digital clinical diagnostics and diabetes home-testing provider Digostics has revealed the results from its ground-breaking gestational diabetes mellitus (GDM) remote screening collaboration with University Hospital Southampton NHS Foundation Trust (UHS), a partnership that saw expectant mothers in Hampshire become the first globally to access an oral-glucose tolerance test (OGTT) without needing to attend clinic.

Cepheid has received clearance from the US Food and Drug Administration for Xpert Xpress GBS, a dual-target molecular diagnostic test for the qualitative intrapartum detection of group B Streptococcus (GBS). This next-generation test incorporates new dual targets in highly-conserved regions of the GBS genome to improve sensitivity and bacterial strain coverage.